Today: 11 June 2026
Browse Category

NYSE:JNJ 6 January 2026 - 17 January 2026

Johnson & Johnson stock slips — what traders watch before JNJ earnings

Johnson & Johnson stock slips — what traders watch before JNJ earnings

Johnson & Johnson shares closed down 0.41% at $218.66 Friday and were flat after hours. The company reports fourth-quarter earnings January 21, with investors watching for updates on drug approvals and MedTech growth. FDA fast-track reviews and consumer-health deals remain in focus. Kenvue, spun off from J&J, faces a key shareholder vote January 29 on its sale to Kimberly-Clark.
17 January 2026
··
Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson shares rose 2.3% to $218.55 in after-hours trading Wednesday after reporting its Tecvayli drug cut the risk of disease progression or death by 71% in a late-stage multiple myeloma trial. An independent committee recommended unblinding the study. Full results will be presented at an upcoming medical meeting. Investors await the company’s quarterly results next week.
15 January 2026
···
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
Johnson & Johnson stock pops on court win — what traders watch before earnings

Johnson & Johnson stock pops on court win — what traders watch before earnings

Johnson & Johnson shares rose 1.9% to $213.65 Tuesday and held steady after hours as Delaware’s top court ordered a recalculation of a $1 billion damages award tied to the Auris Health acquisition. The ruling could reduce the payout by several hundred million dollars. Investors are watching for J&J’s fourth-quarter results on Jan. 21 and updates from healthcare conferences this week.
14 January 2026
··
Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson shares rose 1.6% to $212.98 Tuesday, outperforming a dip in healthcare stocks. Delaware’s Supreme Court ordered a recalculation of part of a $1 billion damages award tied to the Auris acquisition, which could reduce the payout by hundreds of millions. Legal developments and upcoming drug trial data are in focus ahead of the company’s Jan. 21 earnings call.
13 January 2026
···
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson shares fell 0.7% to $204.39 after announcing a deal with the Trump administration to cut U.S. drug prices in exchange for tariff exemptions. The company will offer some medicines at discounted rates via TrumpRx.gov but did not specify drugs or discount sizes. J&J also unveiled plans for two new U.S. manufacturing plants. Early trial data for its cancer drug amivantamab showed a 70% response rate in a first-line subgroup.
11 January 2026
··
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson shares fell 0.7% to $204.39 Friday after the company agreed to lower U.S. drug prices in exchange for tariff exemptions, with terms undisclosed. J&J will join the TrumpRx.gov platform and said it plans two new U.S. manufacturing sites. The S&P 500 rose 0.65%. Investors await the JPMorgan healthcare conference and J&J’s Jan. 21 earnings call.
10 January 2026
··
Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson reached a deal with the Trump administration to cut U.S. drug prices and won exemptions from tariffs on its pharmaceuticals. The company will sell medicines at discounted rates through TrumpRx.gov and announced two new U.S. manufacturing sites. J&J stock closed down 0.7% at $204.39. Terms of the agreement remain confidential.
10 January 2026
····
Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson shares rose 0.5% to $205.41 midday Tuesday after reporting positive Phase 2b results for its lupus drug nipocalimab and announcing plans for Phase 3 trials. The company also filed in Europe to expand use of its myeloma drug combo Tecvayli and Darzalex. J&J continues to face pressure from ongoing talc litigation, with more trials expected this year.
6 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
1 2 3 4 5 6 … 9

Stock Market Today

  • Soybean Prices Rise Amid Anticipation for WASDE Report and Weather Impact
    June 11, 2026, 4:58 AM EDT. Soybeans posted gains of 8 to 11 cents across most contracts on Wednesday, with the national average cash bean price rising 12 cents to $10.70 3/4. Soymeal and soy oil futures also experienced notable increases. Heavy precipitation is expected in key Midwestern states, potentially affecting crop conditions. Traders are awaiting Thursday's World Agricultural Supply and Demand Estimates (WASDE) report, forecasting steady carryout levels for old and new crop soybeans. July and August 2026 soybean futures rose over 10 cents, reflecting market optimism ahead of the report. The weather outlook and WASDE figures remain critical factors driving market activity in soybean trading.

Latest articles

Oracle Stock Moves Higher as AI Backlog Draws Focus

Oracle shares fall after data center spending outlook hits, even as cloud backlog hits new high

11 June 2026
Oracle shares plunged 8.9% in after-hours trading as investors balked at the company’s plan to raise about $40 billion in debt and equity to fund a massive AI data center buildout, despite record revenue and a $638 billion backlog; free cash flow was negative $23.7 billion in fiscal 2026 as capital spending soared, intensifying concerns over whether AI demand will translate into durable profit.
Nvidia Gets AI Approval From Apple But Shares Stay Flat

Nvidia’s $91 Billion Slide Leaves AI Stocks Facing Pressure

11 June 2026
Nvidia plunged 3.73% to $200.42 as investors questioned whether its $91 billion quarterly revenue outlook can withstand rising rates, inflation, and China export restrictions; the selloff hit AI and semiconductor stocks broadly, despite Nvidia’s record sales, making its next quarter’s results a critical test for sustaining its high valuation.
MoneySimpler Moves Into AI Crypto Trading Bots As Market Fills Up

MoneySimpler Moves Into AI Crypto Trading Bots As Market Fills Up

11 June 2026
MoneySimpler launches an AI-powered trading automation platform integrating crypto, forex, and equities for retail users without coding skills, as competition intensifies over dashboard features and AI capabilities; no audited returns or user data disclosed, leaving adoption and real-world performance uncertain.
Go toTop